TD Cowen on Amylyx Pharmaceuticals inc. (AMLX): 'continue to see AMLX as undervalued for the potential of avexitide alone'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Citi on Amylyx Pharmaceuticals inc. (AMLX): 'we think avexitide is well positioned to demonstrate success'
July 14, 2025 8:19 AM EDTCiti analyst Geoff Meacham reiterated a Buy rating and $12.00 price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX).
The analyst comments "Amylyx hosted a KOL event Sunday evening at ENDO 2025 that highlighted the burden of post-bariatric hypoglycemia (PBH), limitations of current management... More
Goldman Sachs Resumes Amylyx Pharmaceuticals inc. (AMLX) at Buy
July 10, 2025 2:23 AM EDTGoldman Sachs analyst Corinne Johnson resumes coverage on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) with a Buy rating and a price target of $10.00.
The analyst comments: "We take a positive view on avexitide, which the company acquired in 2024, for the treatment of post-bariatric surgery hypoglycemia. The asset is highly de-risked following... More
